Phaseline

Companies › Beijing Scitech-Mq Pharmaceuticals

Beijing Scitech-Mq Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ST-1898
Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI
VEGFR2, MET, AXL, PDGFRA, RETPhase 2Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell CarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06359860ST-1898Phase 1Unresectable or Metastatic MelanomaOncologyDec 2026
NCT06127238ST-1898Phase 1Advanced Renal Cell CarcinomaOncologyFeb 2027
NCT06359847ST-1898Phase 2Differentiated Thyroid CarcinomaOncologyDec 2027

Targets

VEGFR2 (1) MET (1) AXL (1) PDGFRA (1) RET (1)

Companies with the same targets

AstraZeneca Exelixis Chia Tai Tianqing Pharmaceutical Group Eli Lilly Johnson & Johnson (Janssen) AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Betta Pharmaceuticals Novartis

Companies built like this

Apollomics Abion Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.